# How Two Phase 3 Trials Measured Desire and Distress Separately

- Article ID: research-304
- Product: PT-141 (pt-141-449)
- Canonical page: https://heritagebiolabs.com/research-library/articles/304-how-two-phase-3-trials-measured-desire-and-distress-separately
- Product collection: https://heritagebiolabs.com/research-library/products/pt-141
- Product page: https://heritagebiolabs.com/product/pt-141-449
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2019, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

A peptide is a short amino-acid chain joined by peptide bonds. A synthetic peptide can be tested for its effect on a defined receptor system and then evaluated for outcomes that matter to people. Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Two older phase 3 studies directly tested the prescription candidate in premenopausal women with hypoactive sexual desire disorder. The 2026 label still summarizes these pivotal comparisons. [1, 2]

Sheryl Kingsberg and colleagues reported two similarly designed double-blind trials. A total of 1,267 women were randomized across the studies. The investigators compared bremelanotide and placebo over 24 weeks and used two main outcomes. One questionnaire measure asked about desire. The other asked about distress associated with low desire. The two measures capture related but distinct experiences; a person can experience a difference in one without an equally large change in the other. [1]

Both trials reported statistically significant average changes favoring bremelanotide on the two primary measures. The pooled differences were modest on the scales used. The number of satisfying sexual events was a separate, secondary measure and did not show a statistically significant change compared with placebo. This is why a report of improved scores for desire and distress should not be rewritten as a proven increase in the number of events. [1, 2]

The studies applied entry criteria and followed participants for a defined period. They also observed more nausea, flushing and headache in the active group. Their results describe average effects and tolerability in the populations studied. They do not predict an individual's response or establish benefit for people outside the labeled population. The trial design is useful because it makes clear which outcomes were supported and which remained uncertain. [1, 2]

## Sources

1. Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology (2019-11). <https://pubmed.ncbi.nlm.nih.gov/31599840/>
2. US Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. Drugs@FDA (revised 2026-10). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 061 - Pinealon and PT-141.docx; article 304; content SHA-256 202d79397f6e985a5437c30dc0754314db664864daf45e95aab624f313cdb2fe.
